Abstract:Background As an age-related syndrome, frailty may play a central role in poor health among older adults. Sarcopenia overlaps with the physical domain of frailty, and most existing studies have analyzed the associated factors of frailty and sarcopenia as an isolated state. Perturbations in metabolism may play an important role in the presence of frailty or sarcopenia; however, the metabolites associated with frailty, especially overlapping with sarcopenia remain unclear. In this study, we aimed to explore whether amino acids, carnitines, acylcarnitines and lysophosphatidylcholines, as specific panels, are significantly correlated with frailty, especially overlapping with sarcopenia, to gain insight into potential biomarkers and possible biological mechanisms and to facilitate their management. Methods We applied a targeted high-performance liquid chromatography-tandem mass spectrometry approach in serum samples from 246 Chinese older men (age 79.2 ± 7.8 years) with frailty ( n = 150), non-frailty ( n = 96), frailty and sarcopenia ( n = 52), non-frail and non-sarcopenic control ( n = 85). Frailty was evaluated using Freid phenotype criteria, sarcopenia was defined by diagnostic algorithm of Asian Working Group on Sarcopenia, and the participants were diagnosed as frailty and sarcopenia when they met the evaluation criteria of both frailty and sarcopenia. A panel of 29 metabolomic profiles was assayed and included different classes of amino acids, carnitines, acylcarnitines, and lysophosphatidylcholines (LPCs). Multivariate logistic regression was used to screen the metabolic factors contributing to frailty status, and orthogonal partial least squares discriminant analysis was used to explore important factors and distinguish different groups. Results In older men demonstrating the frail phenotype, amino acid perturbations included lower tryptophan and higher glycine levels. With regard to lipid metabolism, the frailty phenotype was characterized by lower concentrations of isovalerylcarnitine (C5), LPC16:0 and LPC18:2, while higher levels of octanoyl-L-carnitine (C8), decanoyl-L-carnitine (C10), dodecanoyl-L-carnitine (C12) and tetradecanoyl-L-carnitine (C14). After adjusting for several clinical confounders, tryptophan, LPC18:2, LPC 16:0 and C5 were negatively correlated with frailty, and C8 and C12 were positively related to frailty. We preliminarily identified metabolic profiles (LPC16:0, LPC18:2, glycine and tryptophan) that may distinguish older men with frailty from those without frailty. Importantly, a set of serum amino acids and LPCs (LPC16:0, LPC18:2, and tryptophan) was characterized in the metabotype of older adults with an overlap of frailty and sarcopenia. The metabolites that were most discriminating of frailty status implied that the underlying mechanism might be involved in antioxidation and mitochondrial dysfunction. Conclusions These present metabolic analyses may provide valuable information on the potential biomarkers and possible biological mechanisms of frailty, and overlapping sarcopenia. The findings obtained may offer insight into their management in older adults.

Gut Microbial Features and Circulating Metabolomic Signatures of Frailty in Older Adults

Distinct Serum and Fecal Metabolite Profiles Linking With Gut Microbiome in Older Adults With Frailty

Altered Fecal Microbiota Composition in Older Adults With Frailty

Association of Immunity Markers with the Risk of Incident Frailty: the Rugao Longitudinal Aging Study

Dietary Patterns, Metabolomics and Frailty in a Large Cohort of 120 000 Participants.

IDDF2020-ABS-0141 the Gut Microbiome and Serum Metabolome Orchestrate Healthy Aging and Longevity with Novel Implications for Renal Function

A gut aging clock using microbiome multi-view profiles is associated with health and frail risk

Characterization of the Gut Microbiota in Frail Elderly Patients

The Roles of the Gut Microbiota and Chronic Low-Grade Inflammation in Older Adults With Frailty

Gut microbiome in healthy aging versus those associated with frailty

Association Between Frailty and Gut Microbiota Metabolite TMAO in Older People with Cardiovascular Disease

Specific Metabolites Involved in Antioxidation and Mitochondrial Function Are Correlated With Frailty in Elderly Men

Unraveling the metabolic underpinnings of frailty using multicohort observational and Mendelian randomization analyses

Age‐dependent changes in the gut microbiota and serum metabolome correlate with renal function and human aging

[Research of relationship between frailty and gut microbiota on middle-aged and the aged patients with diabetes].

Exploring the Causal Relationship Between Gut Microbiota and Frailty: a Two-Sample Mendelian Randomization Analysis

Divergent age-associated and metabolism-associated gut microbiome signatures modulate cardiovascular disease risk

Effect of Lactobacillus plantarum BFS1243 on female frailty model induced by fecal microbiota transplantation in germ-free mice

Metabolic clues to aging: exploring the role of circulating metabolites in frailty, sarcopenia and vascular aging related traits and diseases

Frailty and mortality among Chinese at advanced ages.

Frailty Phenotype, Frailty Index and Risk of Mortality in Chinese Elderly Population- Rugao Longevity and Ageing Study.